Literature DB >> 29186515

Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study.

Jue-Sheng Ong1,2, Liang-Dar Hwang1,2, Gabriel Cuellar-Partida1, Nicholas G Martin1, Georgia Chenevix-Trench1, Michael C J Quinn1, Marilyn C Cornelis3, Puya Gharahkhani1, Penelope M Webb4, Stuart MacGregor1.   

Abstract

Background: Coffee consumption has been shown to be associated with various health outcomes in observational studies. However, evidence for its association with epithelial ovarian cancer (EOC) is inconsistent and it is unclear whether these associations are causal.
Methods: We used single nucleotide polymorphisms associated with (i) coffee and (ii) caffeine consumption to perform Mendelian randomization (MR) on EOC risk. We conducted a two-sample MR using genetic data on 44 062 individuals of European ancestry from the Ovarian Cancer Association Consortium (OCAC), and combined instrumental variable estimates using a Wald-type ratio estimator.
Results: For all EOC cases, the causal odds ratio (COR) for genetically predicted consumption of one additional cup of coffee per day was 0.92 [95% confidence interval (CI): 0.79, 1.06]. The COR was 0.90 (95% CI: 0.73, 1.10) for high-grade serous EOC. The COR for genetically predicted consumption of an additional 80 mg caffeine was 1.01 (95% CI: 0.92, 1.11) for all EOC cases and 0.90 (95% CI: 0.73, 1.10) for high-grade serous cases. Conclusions: We found no evidence indicative of a strong association between EOC risk and genetically predicted coffee or caffeine levels. However, our estimates were not statistically inconsistent with earlier observational studies and we were unable to rule out small protective associations.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29186515      PMCID: PMC6186013          DOI: 10.1093/ije/dyx236

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   9.685


  41 in total

1.  Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study.

Authors:  Camilla F Gosvig; Susanne K Kjaer; Jan Blaakær; Estrid Høgdall; Claus Høgdall; Allan Jensen
Journal:  Acta Oncol       Date:  2015-01-28       Impact factor: 4.089

2.  Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption.

Authors:  Patrick Sulem; Daniel F Gudbjartsson; Frank Geller; Inga Prokopenko; Bjarke Feenstra; Katja K H Aben; Barbara Franke; Martin den Heijer; Peter Kovacs; Michael Stumvoll; Reedik Mägi; Lisa R Yanek; Lewis C Becker; Heather A Boyd; Simon N Stacey; G Bragi Walters; Adalbjorg Jonasdottir; Gudmar Thorleifsson; Hilma Holm; Sigurjon A Gudjonsson; Thorunn Rafnar; Gyda Björnsdottir; Diane M Becker; Mads Melbye; Augustine Kong; Anke Tönjes; Thorgeir Thorgeirsson; Unnur Thorsteinsdottir; Lambertus A Kiemeney; Kari Stefansson
Journal:  Hum Mol Genet       Date:  2011-02-28       Impact factor: 6.150

3.  Immediate and highly sensitive aversion response to a novel food item linked to AH receptor stimulation.

Authors:  Sanna Lensu; Jouni T Tuomisto; Jouko Tuomisto; Matti Viluksela; Marjo Niittynen; Raimo Pohjanvirta
Journal:  Toxicol Lett       Date:  2011-03-31       Impact factor: 4.372

4.  Coffee, tea, colas, and risk of epithelial ovarian cancer.

Authors:  Yoon Ju Song; Alan R Kristal; Kristine G Wicklund; Kara L Cushing-Haugen; Mary Anne Rossing
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

5.  Coffee and caffeine intake and the risk of ovarian cancer: the Iowa Women's Health Study.

Authors:  Natalie A Lueth; Kristin E Anderson; Lisa J Harnack; Jayne A Fulkerson; Kim Robien
Journal:  Cancer Causes Control       Date:  2008-08-14       Impact factor: 2.506

6.  Coffee and its chemopreventive components Kahweol and Cafestol increase the activity of O6-methylguanine-DNA methyltransferase in rat liver--comparison with phase II xenobiotic metabolism.

Authors:  Wolfgang W Huber; Gerlinde Scharf; Georg Nagel; Sonja Prustomersky; Rolf Schulte-Hermann; Bernd Kaina
Journal:  Mutat Res       Date:  2003-01-28       Impact factor: 2.433

7.  Association of caffeine intake and CYP1A2 genotype with ovarian cancer.

Authors:  Marc T Goodman; Ko-Hui Tung; Katharine McDuffie; Lynne R Wilkens; Timothy A Donlon
Journal:  Nutr Cancer       Date:  2003       Impact factor: 2.900

Review 8.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

9.  Genetics of coffee consumption and its stability.

Authors:  Venla S Laitala; Jaakko Kaprio; Karri Silventoinen
Journal:  Addiction       Date:  2008-12       Impact factor: 6.526

10.  Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption.

Authors:  Andrea R Josse; Laura A Da Costa; Hannia Campos; Ahmed El-Sohemy
Journal:  Am J Clin Nutr       Date:  2012-08-01       Impact factor: 7.045

View more
  4 in total

1.  Coffee consumption and cancer risk: a Mendelian randomisation study.

Authors:  Paul Carter; Shuai Yuan; Siddhartha Kar; Mathew Vithayathil; Amy M Mason; Stephen Burgess; Susanna C Larsson
Journal:  Clin Nutr       Date:  2022-08-25       Impact factor: 7.643

Review 2.  Causal relationship from coffee consumption to diseases and mortality: a review of observational and Mendelian randomization studies including cardiometabolic diseases, cancer, gallstones and other diseases.

Authors:  Ask T Nordestgaard
Journal:  Eur J Nutr       Date:  2021-07-28       Impact factor: 5.614

Review 3.  Mendelian Randomization Studies of Coffee and Caffeine Consumption.

Authors:  Marilyn C Cornelis; Marcus R Munafo
Journal:  Nutrients       Date:  2018-09-20       Impact factor: 5.717

4.  Systematic review of Mendelian randomization studies on risk of cancer.

Authors:  Georgios Markozannes; Afroditi Kanellopoulou; Olympia Dimopoulou; Dimitrios Kosmidis; Xiaomeng Zhang; Lijuan Wang; Evropi Theodoratou; Dipender Gill; Stephen Burgess; Konstantinos K Tsilidis
Journal:  BMC Med       Date:  2022-02-02       Impact factor: 11.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.